Skip to main content

Table 2 Summary of regimens of the included studies

From: Effect of sofosbuvir-based DAAs on changes in lower-density lipoprotein in HCV patients: a systematic review and meta-analysis

First author (publication year)

No of patients

Group

Regimens

Duration of treatment (week)

Özdoğan (2020)

93

SOF/LDV

NA

12

28

PTVr/OBV + DSV

12

Inoue (2018)

85

SOF/LDV

Harvoni® (SOF 400 mg + LDV 90 mg) QD

12

46

SOF/RBV

Sovaldi® (SOF) 400 mg QD + Rebetol® (RBV) 600/800/1000 mg (depending on body weight) BID

12

85

ASV/DCV

Dacluinza® (DCV) 60 mg QD + Sunbepra® (ASV) 100 mg BID

24

Endo (2017)

132

SOF/LDV

Harvoni® (SOF 400 mg + LDV 90 mg) QD

12

121

ASV/DCV

Dacluinza® (DCV) 60 mg QD + Sunbepra® (ASV) 100 mg BID

24

Kan (2017)

55

SOF/LDV

Harvoni® (SOF 400 mg + LDV 90 mg) QD

12

40

PTVr/OBV

Viekirax® (PTVr 150/100 mg + OBV 25 mg) QD

12

Notsumata (2017)

140

SOF/LDV

NA

12

100

SOF/RBV

12

173

ASV/DCV

24

50

PTVr/OBV

12

Hashimoto (2016)

76

SOF/LDV

Harvoni® (SOF 400 mg + LDV 90 mg) QD

12

24

ASV/DCV

ASV 100 mg + DCV 60 mg BID

24

  1. NS nonstructural proteins; NI non-nucleoside inhibitors; PI protease inhibitors; SOF sofosbuvir; LDV ledipasvir; ASV asunaprevir; DCV daclatasvir; PTVr paritaprevir/ritonavir; OBV ombitasvir; RBV ribavirin; QD once daily; BID twice daily; NA not available